(Q39105350)

English

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

scientific article published on 23 January 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Diego Cortinovis

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Alexis B Cortot

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Denis Moro-Sibilot

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Gilberto de Castro

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Daniel S W Tan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Rita Chiari

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Luis Paz-Ares

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Juergen Wolf

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Sarayut L Geater

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Maximillian Hochmair

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Chun-Ming Tsai

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Rosario G Campelo

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Tracey McCulloch

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Paramita Sen

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Margaret Dugan

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Serafino Pantano

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Fabrice Branle

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Cristian Massacesi

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Jean-Charles Soria

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

language of work or name

0 references

publication date

24 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

10072

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

917-929

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2930123-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)30123-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28126333%20AND%20SRC:MED&resulttype=core&format=json

9 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39105350&oldid=1523895206"